Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy-Reference-Cited by-同舟云学术

Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy

Published:2015-11 Issue:11 Volume:1853 Page:2870-2884
ISSN:0167-4889
Container-title:Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

Author:

Ramos-Kuri Manuel,Rapti Kleopatra,Mehel Hind,Zhang Shihong,Dhandapany Perundurai S.,Liang Lifan,García-Carrancá Alejandro,Bobe Regis,Fischmeister Rodolphe,Adnot Serge,Lebeche Djamel,Hajjar Roger J.,Lipskaia Larissa^ORCID,Chemaly Elie R.^ORCID

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology

Reference45 articles.

1. Rap1 GTPases: an emerging role in the cardiovasculature;Jeyaraj;Life Sci.,2011

2. Small GTP-binding proteins and their regulators in cardiac hypertrophy;Lezoualc'h;J. Mol. Cell. Cardiol.,2008

3. K-ras is essential for the development of the mouse embryo;Koera;Oncogene,1997

4. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development;Esteban;Mol. Cell. Biol.,2001

5. Small guanine nucleotide-binding proteins and myocardial hypertrophy;Clerk;Circ. Res.,2000

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NETWORK TOXICOLOGY FOR THE CARDIOVASCULAR TOXICITY ANALYSIS OF TYROSINE KINASE INHIBITORS;Ankara Universitesi Eczacilik Fakultesi Dergisi;2024-07-24

2. MEK Inhibition for RASopathy-Associated Hypertrophic Cardiomyopathy: Clinical Application of a Basic Concept;Canadian Journal of Cardiology;2024-05

3. Role of gene therapy in treatment of cancer with craniofacial regeneration—current molecular strategies, future perspectives, and challenges: a narrative review;Journal of Yeungnam Medical Science;2024-01-31

4. Gene Therapy for Regenerative Medicine;Pharmaceutics;2023-03-06

5. CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson’s Disease;Pharmaceutics;2022-06-13